NASDAQ:LXRX

Lexicon Pharmaceuticals Stock Forecast, Price & News

$5.19
-0.01 (-0.19 %)
(As of 04/14/2021 12:00 AM ET)
Add
Compare
Today's Range
$5.17
Now: $5.19
$5.39
50-Day Range
$5.07
MA: $6.41
$7.75
52-Week Range
$1.03
Now: $5.19
$9.65
Volume888,627 shs
Average Volume4.50 million shs
Market Capitalization$749.20 million
P/E RatioN/A
Dividend YieldN/A
Beta2.09
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; LX9211, which is in Phase II clinical development for the treatment of neuropathic pain; and LX2761. The company has strategic collaboration and license agreements with Bristol-Myers Squibb Company, and Genentech, Inc. Lexicon Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in The Woodlands, Texas.
Lexicon Pharmaceuticals logo

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:LXRX
Previous SymbolNASDAQ:LEXG
CUSIP52887210
Phone281-863-3000
Employees78
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$322.07 million
Cash Flow$2.33 per share
Book Value$1.10 per share

Profitability

Net Income$130.13 million
Net Margins-320.44%

Miscellaneous

Market Cap$749.20 million
Next Earnings Date4/26/2021 (Estimated)
OptionableOptionable

Headlines

Lexicon Pharmaceuticals (NASDAQ:LXRX) Shares Gap Up to $5.07
April 13, 2021 |  americanbankingnews.com
Lexicon: Q4 Earnings Snapshot
March 10, 2021 |  finance.yahoo.com
Earnings Preview: Lexicon Pharmaceuticals
March 9, 2021 |  benzinga.com
Repligen (RGEN) to Report Q4 Earnings: What's in the Cards?
February 11, 2021 |  finance.yahoo.com
Should You Buy Lexicon Pharmaceuticals Stock?
February 6, 2021 |  fool.com
See More Headlines

MarketRank

Overall MarketRank

1.58 out of 5 stars

Medical Sector

401st out of 2,019 stocks

Pharmaceutical Preparations Industry

189th out of 772 stocks

Analyst Opinion: 3.1Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -
$5.19
-0.01 (-0.19 %)
(As of 04/14/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive LXRX News and Ratings via Email

Sign-up to receive the latest news and ratings for LXRX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Lexicon Pharmaceuticals (NASDAQ:LXRX) Frequently Asked Questions

Is Lexicon Pharmaceuticals a buy right now?

8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Lexicon Pharmaceuticals in the last twelve months. There are currently 6 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" Lexicon Pharmaceuticals stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in LXRX, but not buy additional shares or sell existing shares.
View analyst ratings for Lexicon Pharmaceuticals
or view top-rated stocks.

What stocks does MarketBeat like better than Lexicon Pharmaceuticals?

Wall Street analysts have given Lexicon Pharmaceuticals a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Lexicon Pharmaceuticals wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Lexicon Pharmaceuticals?

Lexicon Pharmaceuticals saw a drop in short interest in the month of March. As of March 31st, there was short interest totaling 3,730,000 shares, a drop of 24.0% from the March 15th total of 4,910,000 shares. Based on an average trading volume of 4,730,000 shares, the short-interest ratio is presently 0.8 days.
View Lexicon Pharmaceuticals' Short Interest
.

When is Lexicon Pharmaceuticals' next earnings date?

Lexicon Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Monday, April 26th 2021.
View our earnings forecast for Lexicon Pharmaceuticals
.

How were Lexicon Pharmaceuticals' earnings last quarter?

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) announced its quarterly earnings results on Wednesday, March, 10th. The biopharmaceutical company reported ($0.05) earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($0.28) by $0.23. The biopharmaceutical company had revenue of $0.20 million for the quarter, compared to analysts' expectations of $0.17 million. Lexicon Pharmaceuticals had a negative trailing twelve-month return on equity of 164.96% and a negative net margin of 320.44%.
View Lexicon Pharmaceuticals' earnings history
.

How has Lexicon Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

Lexicon Pharmaceuticals' stock was trading at $2.27 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, LXRX shares have increased by 128.6% and is now trading at $5.19.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for LXRX?

8 brokers have issued twelve-month target prices for Lexicon Pharmaceuticals' shares. Their forecasts range from $6.00 to $13.00. On average, they expect Lexicon Pharmaceuticals' stock price to reach $9.40 in the next twelve months. This suggests a possible upside of 81.1% from the stock's current price.
View analysts' price targets for Lexicon Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are Lexicon Pharmaceuticals' key executives?

Lexicon Pharmaceuticals' management team includes the following people:
  • Mr. Lonnel Coats, Pres, CEO & Director (Age 56, Pay $1.15M)
  • Mr. Jeffrey L. Wade, Exec. VP of Corp. & Admin. Affairs and CFO (Age 56, Pay $655.18k)
  • Mr. Brian T. Crum, VP, Gen. Counsel & Sec. (Age 48, Pay $536.92k)
  • Dr. Alan J. Main, Exec. VP of Innovation & Chemical Sciences (Age 67, Pay $560.17k)
  • Dr. Praveen Tyle, Exec. VP of R&D (Age 61, Pay $692.31k)
  • Dr. Robert J. Lefkowitz, Consultant & Independent Director (Age 77, Pay $50k)
  • Mr. James F. Tessmer, VP of Fin. & Accounting (Age 61)
  • Chas Schultz, Exec. Director of Corp. Communications & Patient Advocacy

What is Lonnel Coats' approval rating as Lexicon Pharmaceuticals' CEO?

9 employees have rated Lexicon Pharmaceuticals CEO Lonnel Coats on Glassdoor.com. Lonnel Coats has an approval rating of 100% among Lexicon Pharmaceuticals' employees. This puts Lonnel Coats in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Lexicon Pharmaceuticals' key competitors?

What other stocks do shareholders of Lexicon Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Lexicon Pharmaceuticals investors own include Portola Pharmaceuticals (PTLA), Sarepta Therapeutics (SRPT), ACADIA Pharmaceuticals (ACAD), Dynavax Technologies (DVAX), MannKind (MNKD), ImmunoGen (IMGN), Geron (GERN), Micron Technology (MU), TherapeuticsMD (TXMD) and Gilead Sciences (GILD).

What is Lexicon Pharmaceuticals' stock symbol?

Lexicon Pharmaceuticals trades on the NASDAQ under the ticker symbol "LXRX."

Who are Lexicon Pharmaceuticals' major shareholders?

Lexicon Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional shareholders include Boothe Investment Group Inc. (0.30%). Company insiders that own Lexicon Pharmaceuticals stock include Alexander A Santini, Christopher J Sobecki, James F Tessmer, Lonnel Coats and Sam L Barker.
View institutional ownership trends for Lexicon Pharmaceuticals
.

Which institutional investors are buying Lexicon Pharmaceuticals stock?

LXRX stock was acquired by a variety of institutional investors in the last quarter, including Boothe Investment Group Inc.. Company insiders that have bought Lexicon Pharmaceuticals stock in the last two years include Alexander A Santini, Christopher J Sobecki, James F Tessmer, Lonnel Coats, and Sam L Barker.
View insider buying and selling activity for Lexicon Pharmaceuticals
or or view top insider-buying stocks.

How do I buy shares of Lexicon Pharmaceuticals?

Shares of LXRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Lexicon Pharmaceuticals' stock price today?

One share of LXRX stock can currently be purchased for approximately $5.19.

How much money does Lexicon Pharmaceuticals make?

Lexicon Pharmaceuticals has a market capitalization of $749.20 million and generates $322.07 million in revenue each year. The biopharmaceutical company earns $130.13 million in net income (profit) each year or $1.35 on an earnings per share basis.

How many employees does Lexicon Pharmaceuticals have?

Lexicon Pharmaceuticals employs 78 workers across the globe.

What is Lexicon Pharmaceuticals' official website?

The official website for Lexicon Pharmaceuticals is www.lexpharma.com.

Where are Lexicon Pharmaceuticals' headquarters?

Lexicon Pharmaceuticals is headquartered at 8800 TECHNOLOGY FOREST PLACE, THE WOODLANDS TX, 77381.

How can I contact Lexicon Pharmaceuticals?

Lexicon Pharmaceuticals' mailing address is 8800 TECHNOLOGY FOREST PLACE, THE WOODLANDS TX, 77381. The biopharmaceutical company can be reached via phone at 281-863-3000 or via email at [email protected]


This page was last updated on 4/15/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.